---
canonical_name: Apigenin
alternate_names: 4′,5,7-Trihydroxyflavone, Apigenol, Chamomile Flavone
canonical_topic: Apigenin for Health & Longevity
short_topic_lc: apigenin
creation_date: 2026-0716-0142
creator_ai_fullname: Opus 4.8
---

# Apigenin for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 07/16/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** 4′,5,7-Trihydroxyflavone, Apigenol, Chamomile Flavone

  
## Motivation

<!-- This motivation section was written last, after the rest of the document was completed, so that it accurately reflects the full scope of the review. -->

Apigenin is a natural plant pigment in the flavonoid family, found in everyday foods such as parsley, celery, and — most famously — chamomile. It is the compound widely credited for the calming, sleep-friendly reputation of chamomile tea. In recent years it has moved from the teacup to the supplement shelf, sold as a purified powder to people hoping to sleep better, feel calmer, and support long-term cellular health.

Interest from the longevity community grew when laboratory work showed that apigenin can slow the breakdown of a coenzyme the body uses for energy and repair that naturally falls with age. Chamomile preparations rich in apigenin have also been studied in people for sleep and blood-sugar control, and the compound is a heavily researched candidate in cancer and inflammation laboratories, though most of that work remains in cells and animals.

This review examines what is currently known about apigenin as it relates to health and longevity: how it is thought to work, which benefits are supported by human evidence and which rest only on early laboratory findings, its safety profile and interactions, and the practical questions of dose, form, and quality that shape how it is used.

  
**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

This section lists high-quality, high-level resources that discuss apigenin — or its central mechanisms of sleep support and NAD+ (nicotinamide adenine dinucleotide, a coenzyme central to energy and cellular repair that declines with age) preservation — in substantial depth.

<!-- A real-time web search and on-site searches were performed across the priority expert platforms (FoundMyFitness, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension) plus general web and PubMed for apigenin-focused overviews. Rhonda Patrick discusses apigenin (sleep, CD38/NAD+) only within broader FoundMyFitness Q&A episodes rather than in a single dedicated deep-dive, and no dedicated Chris Kresser piece on apigenin was found; the items below were selected for topical depth and eligibility. -->

* [Toolkit for Sleep](https://www.hubermanlab.com/newsletter/toolkit-for-sleep) - Andrew Huberman

  A practitioner-facing protocol newsletter that places apigenin (about 50 mg before bed) within a broader sleep-supplement stack, explaining its calming effect through GABA (gamma-aminobutyric acid, the brain's primary calming signal) and where it fits relative to magnesium and theanine.

* [How metabolic and immune system dysfunction drive the aging process, the role of NAD, promising interventions, aging clocks, and more](https://peterattiamd.com/ericverdin/) - Peter Attia

  A long-form conversation with NAD+ researcher Eric Verdin covering NAD+ and the enzyme CD38 (which breaks down NAD+) — the exact biology that underlies apigenin's proposed longevity rationale.

* [Superfoods: Chamomile Tea](https://www.lifeextension.com/magazine/2024/8/chamomile-tea-superfoods) - Laurie Mathena

  A consumer-oriented overview of chamomile that identifies apigenin as a key active flavonoid and summarizes human findings for sleep quality and blood-sugar control, useful for understanding apigenin as it is most commonly consumed.

* [Apigenin: a natural molecule at the intersection of sleep and aging](https://pubmed.ncbi.nlm.nih.gov/38476603/) - Kramer & Johnson, 2024

  A narrative review that synthesizes apigenin's sleep, sedative, and longevity-relevant effects across worm, fly, mouse, and human data, and is the single most focused overview of the sleep–aging link that motivates longevity interest.

* [The Therapeutic Potential of Apigenin](https://pubmed.ncbi.nlm.nih.gov/30875872/) - Salehi et al., 2019

  A broad narrative review of apigenin's chemistry, dietary sources, absorption limits, and the full breadth of its studied anti-inflammatory, anticancer, and neuroprotective activities, serving as a comprehensive scientific primer.

  Note on priority experts: no dedicated apigenin deep-dive was found for two of the priority sources — Rhonda Patrick discusses apigenin (sleep, CD38/NAD+) only within broader FoundMyFitness Q&A episodes rather than in a standalone piece, and no dedicated Chris Kresser article on apigenin was found.

  
## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool by navigating to the site's Apigenin page; a dedicated article was confirmed to exist. -->

* [Apigenin](https://grokipedia.com/page/Apigenin)

  Grokipedia hosts a dedicated, continuously updated encyclopedia entry on apigenin covering its chemistry, dietary sources, pharmacology, and studied biological effects, providing a broad reference overview of the compound.

  
## Examine

<!-- examine.com was searched directly using the browser tool; a dedicated apigenin supplement page was confirmed to exist at examine.com/supplements/apigenin. -->

* [Apigenin benefits, dosage, and side effects](https://examine.com/supplements/apigenin/)

  Examine's independent, evidence-graded supplement page summarizes apigenin's effects, dosing, and safety, and is notable for candidly flagging its poor absorption and the current lack of human trials on the isolated compound.

  
## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool; a dedicated apigenin answer article was confirmed to exist. -->

* [What are the health effects of apigenin and is it safe?](https://www.consumerlab.com/answers/apigenin-health-effects-and-safety/apigenin/)

  ConsumerLab reviews the evidence and safety of apigenin as promoted for sleep, mood, and other conditions, and periodically publishes clinical updates on apigenin for cognition and menopause, giving a consumer-protection lens on the supplement.

  
## Systematic Reviews

A real-time PubMed search for apigenin combined with "systematic review OR meta-analysis" returned the most relevant, recent, and citation-weighted syntheses below; the evidence base is dominated by preclinical work, and no meta-analysis of randomized human trials of isolated apigenin currently exists.

* [Protective Roles of Apigenin Against Cardiometabolic Diseases: A Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/35495935/) - Xu et al., 2022

  This review synthesizes preclinical and limited clinical evidence that apigenin improves markers of high blood pressure, blood lipids, insulin resistance, and vascular function, mainly through anti-inflammatory and antioxidant actions. It underscores that most supporting data come from cell and animal models.

* [Role of apigenin in targeting metabolic syndrome: A systematic review.](https://pubmed.ncbi.nlm.nih.gov/38629096/) - Javadi & Sobhani, 2024

  A focused synthesis of apigenin's effects on the clustered features of metabolic syndrome — obesity, high blood sugar, dyslipidemia (abnormal blood fats), and hypertension — describing consistent benefit in animal models via AMPK (a cellular energy sensor) and PPAR (receptors that regulate fat and glucose metabolism) signaling. Human confirmation is identified as the key missing piece.

* [The Beneficial Role of Apigenin against Cognitive and Neurobehavioural Dysfunction: A Systematic Review of Preclinical Investigations.](https://pubmed.ncbi.nlm.nih.gov/38255283/) - Olasehinde & Olaokun, 2024

  This review evaluates preclinical studies showing apigenin improves learning, memory, and anxiety-like behavior in rodent models of neurodegeneration and stress, attributing effects to reduced neuroinflammation and oxidative stress. It explicitly notes the absence of confirmatory human trials.

* [Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models.](https://pubmed.ncbi.nlm.nih.gov/35752426/) - Singh et al., 2022

  A meta-analysis of animal tumor studies finding that apigenin significantly reduced tumor volume and weight across multiple cancer models. The authors caution that translation to humans is unproven and constrained by apigenin's poor bioavailability.

* [Potential therapeutic effects of apigenin for colorectal adenocarcinoma: A systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/39254067/) - Ahmadzadeh et al., 2024

  This synthesis of in vitro and animal colorectal-cancer studies reports dose-dependent inhibition of cancer-cell growth and tumor progression with apigenin. It reinforces a consistent preclinical signal while highlighting the lack of clinical data.

  
## Mechanism of Action

Apigenin is a flavone (a subclass of flavonoid) with the chemical name 4′,5,7-trihydroxyflavone. It is not a single-target drug; it interacts with many proteins at once, which explains both its broad range of reported effects and the difficulty of pinning down one dominant mechanism. The following pathways are the most consistently reported.

* **NAD+ preservation via CD38 inhibition:** Apigenin blocks CD38, the main enzyme that consumes NAD+ (nicotinamide adenine dinucleotide) inside cells and tissues. Because NAD+ falls with age and fuels energy metabolism, DNA repair, and the sirtuin family of longevity enzymes (proteins such as SIRT1 and SIRT3 that help regulate metabolism and stress resistance), slowing its breakdown is the principal reason apigenin is discussed as a longevity compound. In obese mice, apigenin raised tissue NAD+ and improved metabolic markers; equivalent human data do not yet exist.

* **Anti-inflammatory signaling:** Apigenin dampens NF-κB (nuclear factor kappa B, a master switch that turns on inflammatory genes) and inhibits the NLRP3 inflammasome (a protein complex that triggers release of inflammatory messengers). This lowers pro-inflammatory signals such as TNF-α (tumor necrosis factor alpha) and interleukins and is the mechanism most often invoked for its effects on inflammation, immunity, and senescent ("aged") cells.

* **Antioxidant defense:** It activates Nrf2 (a protein that switches on the cell's built-in antioxidant genes), increasing protective enzymes and reducing oxidative stress. It also modulates AMPK and can suppress mTOR (a growth-signaling pathway linked to aging), broadly aligning apigenin with other stress-resistance interventions.

* **Nervous-system effects:** Apigenin binds to the benzodiazepine site of the GABA-A receptor, producing mild calming and sedative effects without strong sedation, and modulates GABA turnover. This is the basis for chamomile's traditional use for sleep and anxiety.

* **Hormone and enzyme modulation:** Apigenin can inhibit aromatase (the enzyme that converts androgens into estrogen) and shows both weak estrogen-like and anti-estrogenic activity depending on tissue and dose. It also inhibits several cytochrome P450 (CYP) liver enzymes and drug transporters, which is central to its interaction profile.

Where mechanisms compete, the picture is genuinely mixed: some anti-inflammatory effects appear to be independent of CD38, and apigenin's hormonal actions can point in opposite directions across tissues, so no single unifying mechanism fully accounts for its observed effects.

Key pharmacological properties: apigenin is poorly water-soluble and poorly absorbed, with low oral bioavailability; it is extensively metabolized by glucuronidation and sulfation (via UGT and SULT enzymes) and by gut bacteria, and undergoes enterohepatic recirculation, which gives it a relatively long and variable elimination half-life estimated at roughly 12 hours or more. It distributes widely but reaches only low concentrations in blood after oral dosing.

  
## Historical Context & Evolution

* **Original use:** Apigenin was never developed as a drug. It entered human use indirectly, as the active flavonoid in chamomile (*Matricaria chamomilla* and *Chamaemelum nobile*), which has been used for centuries as a herbal tea and folk remedy for restlessness, digestive complaints, and poor sleep. It was later isolated and catalogued as a natural yellow dye and a common dietary flavonoid.

* **Why it came to be studied for health optimization:** From the late twentieth century, flavonoids attracted research attention as dietary antioxidants, and apigenin stood out for its anti-inflammatory and anticancer activity in cell studies. Its profile broadened as laboratories reported neuroprotective, sedative, and metabolic effects.

* **The longevity turn:** A pivotal 2013 laboratory study identified apigenin as an inhibitor of CD38, linking it directly to NAD+ metabolism. As NAD+ decline became a central theme in aging biology and NAD+-boosting supplements gained popularity, apigenin was repositioned as a way to protect NAD+ by reducing its breakdown, complementing precursors that supply more of it.

* **Evolving evidence:** The findings themselves — tumor suppression in animals, CD38 inhibition, sleep and anxiety effects of chamomile — have generally held up on repetition, but their standing for human health remains open rather than settled. The main development over time has been growing recognition that apigenin's poor absorption may limit how much of this preclinical promise reaches human tissues, which has shifted research toward improved delivery formulations rather than overturning the underlying biology.

  
## Expected Benefits

The benefit profile below was compiled from clinical and expert sources, systematic reviews, and PubMed searches for apigenin's full range of studied effects. A central caveat frames the entire section: most human evidence comes from chamomile extracts (which deliver apigenin alongside other compounds) rather than from isolated apigenin, and the remainder is preclinical. Benefits are therefore weighted conservatively for a proactive, health-focused adult evaluating apigenin as a supplement.

### Medium 🟩 🟩

#### Sleep Quality and Reduced Anxiety ⚠️ Conflicted

Apigenin's binding to calming GABA-A receptors provides a plausible mechanism for its traditional role as a mild sleep and anxiety aid, and it is the most human-tested benefit because chamomile extracts standardized to apigenin have been evaluated in randomized controlled trials (RCTs — studies that randomly assign participants to treatment or placebo). Results are directly conflicted: some trials in older adults and people with generalized anxiety reported improved sleep quality and reduced anxiety scores, while a well-conducted pilot study in chronic insomnia found no significant benefit on the main sleep outcomes. The effect, where present, is modest and may reflect other chamomile constituents rather than apigenin alone. It is best characterized as a gentle, relaxation-promoting effect rather than a reliable sedative.

**Magnitude:** In positive chamomile-extract trials, sleep-quality and anxiety questionnaire scores improved modestly (on the order of a few points on standard scales); other trials showed no significant change in time to fall asleep or total sleep time.

### Low 🟩

#### Blood Sugar and Lipid Regulation

Apigenin improves insulin sensitivity, lowers blood glucose, and improves cholesterol profiles in animal models of metabolic syndrome, acting through AMPK activation, reduced inflammation, and improved fat metabolism. The main human signal comes from chamomile-tea trials in type 2 diabetes reporting improved blood-sugar and lipid markers, supported by two systematic reviews of apigenin's cardiometabolic effects. Because the human data use chamomile rather than isolated apigenin and involve small samples, the evidence is graded Low despite being biologically consistent.

**Magnitude:** An 8-week chamomile-tea trial in type 2 diabetes reported reductions in HbA1c (a measure of average blood sugar over about three months), total cholesterol, and LDL (low-density lipoprotein) cholesterol of roughly a few percent to ~25 mg/dL; isolated-apigenin human data are lacking.

#### Systemic Inflammation Reduction

By suppressing NF-κB and the NLRP3 inflammasome, apigenin lowers inflammatory signaling across many tissues, a mechanism relevant to the chronic low-grade inflammation associated with aging. The strongest human hint is a small trial in elderly patients with sepsis in which apigenin was added to standard care and organ-function scores were tracked, alongside extensive preclinical anti-inflammatory data. The evidence in healthy or generally well adults remains indirect, so the grade is Low.

**Magnitude:** A small pilot trial in elderly sepsis patients tracked organ-function (SOFA) scores over 96 hours; the size of any anti-inflammatory benefit in healthy adults is not quantified in available studies.

### Speculative 🟨

#### NAD+ Preservation and Longevity Signaling

This is the mechanism that draws the longevity community to apigenin: by inhibiting CD38, it could slow the age-related loss of NAD+ and thereby support sirtuin activity, energy metabolism, and cellular repair. The supporting evidence is entirely preclinical — apigenin raised NAD+ and improved metabolic and lifespan-related markers in mice, flies, and worms — with no human study yet showing that oral apigenin measurably raises NAD+ or affects biological aging. It is included because it is the primary rationale for longevity use, but it rests on mechanistic and animal data only.

#### Cancer Risk Reduction

Apigenin consistently suppresses tumor-cell growth, migration, and survival in cell and animal studies across breast, colorectal, prostate, and other cancer models, and dietary-flavonoid epidemiology weakly associates higher intake with lower risk of some cancers. No clinical trial has tested apigenin for cancer prevention or treatment in people, and its poor absorption raises doubt about achieving active tissue levels. The basis is preclinical and observational only.

#### Cognitive and Neuroprotective Effects

In rodent models, apigenin improves learning and memory, reduces neuroinflammation, and protects neurons in models of Alzheimer's disease, Parkinson's disease, and stress. A systematic review of these preclinical studies found a consistent protective signal, and the CD38/NAD+ and anti-inflammatory mechanisms are biologically plausible for brain aging. Because no controlled human cognitive trials of apigenin exist, the benefit is mechanistic and animal-based only.

  
## Benefit-Modifying Factors

* **Gut microbiome composition:** Much dietary apigenin arrives bound to sugars (as glycosides such as apiin) that must be freed by bacterial enzymes before absorption; individuals with different gut flora extract and absorb apigenin very differently, which likely modifies any benefit.

* **Baseline inflammation and metabolic status:** Anti-inflammatory and metabolic benefits are most plausible in people who start with elevated inflammation, poor blood-sugar control, or metabolic syndrome; those already optimized may see little measurable change.

* **Baseline sleep and anxiety:** The sleep and calming effects are more likely to be noticeable in people with poor sleep quality or elevated anxiety than in good sleepers, mirroring the pattern seen in chamomile trials.

* **Age:** Because NAD+ decline and CD38 activity increase with age, the NAD+-preserving rationale is theoretically more relevant to older adults; however, this remains unproven in humans.

* **Sex and hormonal status:** Apigenin's effects on aromatase and estrogen signaling mean that hormonal context — pre- versus post-menopausal status in women, and baseline estrogen levels in both sexes — may modify both metabolic and tissue-specific responses.

* **Genetic differences in metabolism:** Variation in UGT and SULT enzymes and in drug transporters affects how quickly apigenin is cleared, plausibly influencing tissue exposure and response, though no validated pharmacogenetic guidance exists.

  
## Potential Risks & Side Effects

Apigenin has a reassuring safety record: it is a common dietary component, and human chamomile trials report few adverse effects. A dedicated search of drug-reference and supplement-safety sources (Examine, ConsumerLab, and the pharmacology literature) found no serious toxicity signal for typical supplemental doses, but also very limited formal safety data on the isolated compound. The risks below are therefore weighted toward drug interactions and theoretical concerns rather than direct toxicity.

### Low 🟥

#### Cytochrome P450 and Drug-Metabolism Interference

Apigenin inhibits several cytochrome P450 liver enzymes (including CYP1A2, CYP2C9, and CYP3A4 — enzymes that break down many medications) as well as UGT enzymes and drug transporters. In principle this can raise blood levels of co-administered drugs, increasing their effects and side effects. The evidence is largely from in vitro and animal studies, so the real-world magnitude in people taking supplemental doses is uncertain but plausible enough to warrant caution, especially with narrow-therapeutic-index medications.

**Magnitude:** Not quantified in available studies.

#### Estrogen-Pathway Modulation

Because apigenin can both inhibit aromatase and interact with estrogen receptors, it may nudge estrogen signaling up or down depending on tissue and dose. This is relevant for people with hormone-sensitive conditions and for anyone relying on stable estrogen levels. The concern is grounded in consistent laboratory findings but has not been shown to cause clinical problems at dietary or typical supplemental intakes.

**Magnitude:** Not quantified in available studies.

#### Additive Sedation and Drowsiness

Through its calming GABA-A activity, apigenin can add to the drowsiness caused by alcohol, sedatives, sleep medications, and other calming supplements, potentially causing excess sedation or impaired alertness. The effect from apigenin alone is mild, and reports come mainly from chamomile use and mechanistic reasoning rather than controlled studies.

**Magnitude:** Not quantified in available studies.

### Speculative 🟨

#### Bleeding Potentiation

Chamomile preparations contain coumarin compounds and have been linked in isolated case reports to increased bleeding when combined with blood thinners such as warfarin, and apigenin may inhibit platelet activity. Whether isolated apigenin meaningfully raises bleeding risk is unestablished, resting on case reports involving chamomile and on mechanistic plausibility rather than trials of the pure compound.

#### Allergic Reactions

Apigenin sourced from chamomile or other plants in the daisy (Asteraceae) family can carry trace allergens, and people allergic to ragweed, chamomile, or related plants have experienced allergic reactions ranging from rash to, rarely, anaphylaxis. This risk relates to plant-derived preparations rather than the purified molecule, and reports are isolated.

#### High-Dose and Pregnancy-Related Effects

Safety data for high supplemental doses, and for use during pregnancy and breastfeeding, are essentially absent; apigenin's hormonal and uterine activity in laboratory models is the basis for a precautionary concern. No human toxicity has been documented at typical intakes, so this remains a theoretical, data-gap concern rather than an observed harm.

  
## Risk-Modifying Factors

* **Concurrent medications (polypharmacy):** The dominant risk modifier is other drugs. People taking medications metabolized by CYP1A2, CYP2C9, or CYP3A4 — or taking blood thinners, sedatives, or hormone therapies — face the greatest interaction risk, which rises with the number of medications.

* **CYP2C9 genetic status:** Poor metabolizers at CYP2C9 already clear drugs such as warfarin slowly; added enzyme inhibition from apigenin could further raise levels of such drugs, amplifying bleeding or other dose-related risks.

* **Hormone-sensitive conditions:** Individuals with estrogen-sensitive cancers, endometriosis, or on hormone-modulating therapy have more to consider given apigenin's estrogen-pathway activity, making baseline hormonal status a key modifier.

* **Bleeding disorders and surgery:** Those with clotting disorders, or approaching surgery, are more vulnerable to any antiplatelet or coumarin-related bleeding effect.

* **Sex:** Because of the estrogen-related actions, women — particularly around menopause — may experience hormonal effects differently than men, though clinical consequences are unproven.

* **Age and liver function:** Older adults and those with reduced liver function metabolize apigenin and interacting drugs less efficiently and are more likely to be on multiple medications, raising the practical interaction risk.

  
## Key Interactions & Contraindications

* **Blood thinners and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin):** Caution — potential additive or potentiated bleeding through platelet inhibition and possible CYP2C9 interference with warfarin. Mitigation: avoid combining without medical oversight; if used, monitor INR (a standard blood-clotting test) closely and watch for bruising or bleeding.

* **CYP3A4 substrates (statins such as simvastatin, certain calcium-channel blockers, some immunosuppressants):** Caution — apigenin's enzyme inhibition may raise drug levels and side effects. Mitigation: separate dosing where feasible and monitor for drug-specific side effects; involve a prescriber for narrow-therapeutic-index agents.

* **CYP1A2 and CYP2C9 substrates (theophylline, some NSAIDs — non-steroidal anti-inflammatory painkillers, phenytoin):** Caution — raised drug exposure is plausible. Mitigation: monitor for enhanced effects; consider dose review with a clinician.

* **Sedatives and CNS (central nervous system) depressants — prescription and over-the-counter (benzodiazepines, "Z-drugs," opioids, antihistamines such as diphenhydramine, alcohol):** Caution — additive drowsiness and impaired alertness via shared GABA-A activity. Mitigation: avoid stacking multiple sedatives; do not combine with alcohol before driving or operating machinery.

* **Over-the-counter NSAIDs (ibuprofen, naproxen):** Caution — additive bleeding risk when combined with any antiplatelet effect. Mitigation: limit concurrent use, especially before procedures.

* **Blood-sugar-lowering drugs (metformin, sulfonylureas, insulin):** Monitor — apigenin's glucose-lowering tendency may be additive and could contribute to low blood sugar. Mitigation: monitor glucose when starting; watch for hypoglycemia symptoms.

* **Supplement interactions:** Additive sedation with other calming supplements (valerian, magnesium, L-Theanine, melatonin); additive CYP inhibition with grapefruit-derived products and other flavonoid extracts. Monitor for excess drowsiness or altered drug effects.

* **Supplements with additive/complementary effects:** NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) are frequently paired with apigenin on the theory that apigenin reduces NAD+ breakdown while precursors supply more; this pairing is complementary rather than hazardous but remains unproven in humans.

* **Populations who should avoid or seek guidance first:** pregnant or breastfeeding women (absence of safety data plus hormonal activity); people with hormone-sensitive cancers or conditions; those on warfarin or with bleeding disorders; anyone scheduled for surgery within about two weeks (stop beforehand to reduce bleeding risk); and people with known chamomile, ragweed, or other Asteraceae-family allergy.

  
## Risk Mitigation Strategies

* **Start low and assess tolerance:** Begin at a low dose (for example, the ~50 mg used in sleep protocols) rather than high research-scale amounts, to gauge sedation and individual response before considering any increase — mitigating excess drowsiness and unexpected reactions.

* **Screen the full medication list first:** Before use, review all prescription and over-the-counter drugs for CYP1A2/2C9/3A4 substrates, blood thinners, sedatives, and glucose-lowering agents — mitigating the drug-interaction risks that are apigenin's main hazard.

* **Separate timing from critical medications:** Take apigenin several hours apart from narrow-therapeutic-index drugs where separation is feasible, and preferentially at night when sedation is desirable — reducing peak enzyme-inhibition overlap and daytime drowsiness.

* **Stop before surgery:** Discontinue apigenin (and apigenin-rich chamomile supplements) at least 1–2 weeks before any planned surgery or dental procedure — mitigating potential additive bleeding.

* **Monitor when combining with glucose- or clot-affecting therapy:** Check blood glucose when pairing with diabetes medication and monitor INR when unavoidable alongside warfarin — mitigating hypoglycemia and bleeding, respectively.

* **Avoid in higher-risk groups:** Do not use during pregnancy or breastfeeding, and seek medical advice first with hormone-sensitive conditions — mitigating the theoretical hormonal and developmental concerns.

* **Choose allergy-appropriate, tested products:** People with daisy-family allergies should favor synthetically produced or highly purified apigenin over crude chamomile extracts, and select third-party-tested products — mitigating allergic reactions and contaminant exposure.

  
## Therapeutic Protocol

* **Common supplemental dose:** The most widely used protocol is roughly 50 mg of apigenin taken about 30–60 minutes before bed, popularized within sleep-supplement stacks by practitioners such as Andrew Huberman. This reflects the sleep/calming use rather than a validated longevity dose.

* **Higher and research doses:** Some supplements and studies use higher amounts (in the hundreds of milligrams), but there is no established, human-validated dose for longevity, NAD+ support, or metabolic benefit; higher doses increase interaction concerns without proven added benefit.

* **Food and chamomile alternatives:** Apigenin is also obtained from chamomile tea or standardized chamomile extract and from dietary sources such as parsley and celery; chamomile preparations are the form with the most human data but deliver variable apigenin amounts.

* **Competing approaches:** Two broad approaches coexist without one being clearly superior — a "whole-plant" approach using chamomile extract standardized to apigenin (favored in traditional and integrative practice for sleep), and an "isolated-compound" approach using purified or enhanced-bioavailability apigenin (favored in the longevity/biohacking community for CD38/NAD+ goals).

* **Best time of day:** Evening dosing is generally preferred because of the mild sedative effect; daytime use risks drowsiness. For non-sleep goals, timing is not well defined.

* **Half-life and dosing frequency:** Apigenin's long but variable elimination (estimated around 12 hours or more, extended by enterohepatic recirculation) means once-daily evening dosing is typical; splitting doses is generally unnecessary and could add daytime sedation.

* **Genetic considerations:** No validated pharmacogenetic dosing exists, but CYP2C9 poor metabolizers on interacting drugs and individuals with low gut-bacterial deglycosylation capacity may experience atypical exposure and should be more conservative.

* **Sex-based considerations:** Given aromatase and estrogen-receptor activity, women — especially peri- and post-menopausal — may wish to consider hormonal context; dosing differences between sexes are not established.

* **Age-related considerations:** Older adults, who often take more medications and clear compounds more slowly, should emphasize the low-and-slow approach and interaction screening; the theoretical NAD+ rationale is most often invoked for this group.

* **Baseline biomarkers:** Baseline inflammation, glucose, lipids, and (where relevant) hormonal markers help contextualize whether any metabolic or inflammatory benefit is plausible and give a reference point for tracking.

* **Pre-existing conditions:** Those with metabolic syndrome or poor sleep are the most plausible responders; those with hormone-sensitive or bleeding conditions require caution before starting.

  
## Discontinuation & Cycling

* **Lifelong vs short-term:** Apigenin is not a medication requiring continuous lifelong use; it can reasonably be used short-term (for sleep or a defined trial period) or ongoing, and there is no evidence that indefinite use is necessary or harmful.

* **Withdrawal effects:** No characteristic withdrawal syndrome has been reported. Because it acts mildly on calming GABA pathways, abrupt stopping after regular use as a sleep aid could in theory be followed by a night or two of poorer sleep (rebound), though this is not well documented.

* **Tapering:** Formal tapering is generally not required given the mild effect and lack of dependence data; those using it nightly for sleep may prefer to reduce gradually simply to observe any rebound.

* **Cycling:** No evidence supports a need to cycle apigenin to maintain efficacy, and tolerance has not been described; cycling is neither established as beneficial nor known to be necessary.

* **Practical framing:** Discontinuation is best treated as a straightforward trial-and-observe decision — stop, watch sleep and how one feels, and reassess — rather than following a fixed protocol.

  
## Sourcing and Quality

* **Purity and third-party testing:** Because supplement quality is unregulated, products should carry third-party testing or certification (for example, from independent laboratories) confirming apigenin content and screening for heavy metals, solvents, and microbial contaminants.

* **Form and bioavailability:** Standard apigenin is poorly absorbed; formulations designed to improve uptake — micronized powder, liposomal preparations, phospholipid complexes, or nanoparticle carriers, sometimes combined with absorption enhancers — are more likely to deliver meaningful amounts and are worth prioritizing.

* **Source material:** Apigenin is offered both as chamomile-derived extract (standardized to a stated apigenin percentage) and as high-purity isolated or synthetic apigenin; the labeled apigenin content and standardization matter more than the marketing source, and allergy-prone users should prefer purified forms.

* **Reputable suppliers:** Established supplement brands that publish certificates of analysis and use recognized testing programs are preferable to unbranded bulk powders; compounding pharmacies may offer standardized apigenin where available.

* **Label scrutiny:** Products should clearly state the actual apigenin dose per serving (not just "chamomile extract"), the standardization percentage, and the delivery form, since these determine how much active compound is actually provided.

  
## Practical Considerations

* **Time to effect:** The calming/sleep effect is acute, felt within about 30–60 minutes of an evening dose. Any anti-inflammatory or metabolic effects would build over weeks and are subtle; longevity-related effects, if real, would not be perceptible and could only be inferred from biomarkers over months.

* **Common pitfalls:** The most frequent mistakes are expecting a strong sedative effect (apigenin is mild), overlooking poor bioavailability by using un-enhanced powder, assuming isolated-apigenin benefits from what is really chamomile evidence, and combining it with other sedatives or interacting medications without checking.

* **Regulatory status:** Apigenin is sold as a dietary supplement, not an approved drug; it is not evaluated by the FDA for safety or efficacy, and no health claims are authorized. It is legal and widely available.

* **Cost and accessibility:** Apigenin is inexpensive and easy to obtain online and in supplement shops; enhanced-bioavailability formulations cost more but remain modestly priced. Neither cost nor access is a meaningful barrier.

  
## Interaction with Foundational Habits

* **Sleep:** Direct, potentiating. Apigenin's calming GABA-A activity is the basis for its most common use; taken in the evening it may modestly ease sleep onset and reduce pre-sleep anxiety. Practical note: dose 30–60 minutes before bed and avoid daytime use to prevent drowsiness; effects are gentle and best combined with good sleep hygiene rather than relied on alone.

* **Nutrition:** Indirect, complementary. Apigenin is itself a dietary compound found in parsley, celery, and chamomile, so a plant-rich diet contributes background intake. Because it is fat-soluble and poorly absorbed, taking supplements with a meal containing some fat may aid uptake; whole-diet flavonoid intake is the realistic route to its metabolic effects.

* **Exercise:** Indirect, potentiating. Apigenin's anti-inflammatory and antioxidant actions could theoretically support recovery from the inflammatory stress of training, and its metabolic effects align with exercise's benefits; there is no evidence it blunts training adaptations. Timing around workouts is not established, and evening dosing fits its sedative profile better than pre-workout use.

* **Stress management:** Direct, potentiating. Via calming GABA pathways, apigenin may take the edge off anxiety and support relaxation, complementing practices such as breathing exercises or meditation and potentially easing the stress response; it is a mild adjunct, not a substitute for behavioral stress management.

  
## Monitoring Protocol & Defining Success

Formal laboratory monitoring is not required for most people using low-dose apigenin, given its safety and the absence of validated biomarkers of effect. The measures below are optional and most useful for those using apigenin for metabolic or inflammatory goals, taking interacting medications, or wanting an objective reference point. Baseline testing establishes a starting picture before use.

Ongoing monitoring is modest: for those tracking metabolic or inflammatory goals, re-checking relevant markers at about 3 months, then every 6–12 months, is reasonable; those on interacting medications should follow the monitoring their clinician sets for those drugs (for example, INR checks when combined with warfarin).

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| --------- | ------------------------ | --------------- | ------------- |
| hs-CRP | < 1.0 mg/L | Tracks systemic inflammation, apigenin's proposed target | High-sensitivity C-reactive protein. Fasting not required; avoid testing during acute illness or injury, which transiently raises it |
| Fasting glucose | 70–90 mg/dL | Gauges blood-sugar effect for metabolic users | Requires 8–12 h fasting; pair with fasting insulin for insulin-sensitivity context |
| HbA1c | < 5.4% | Reflects average blood sugar over ~3 months | No fasting needed; conventional "normal" extends to 5.6%, but functional targets are tighter |
| Fasting lipid panel | Triglycerides < 80 mg/dL; HDL > 50 mg/dL | Captures the lipid changes seen in chamomile trials | HDL = high-density lipoprotein. 8–12 h fasting; best interpreted alongside glucose markers |
| ALT / AST | < 25 U/L | Safety check at higher doses given hepatic metabolism | ALT and AST are liver enzymes. Conventional labs allow up to ~40 U/L; morning draw, avoid intense exercise beforehand |
| Estradiol (if hormonally relevant) | Sex- and age-appropriate range | Contextualizes apigenin's estrogen-pathway activity | Time to cycle phase in premenopausal women; optional, for hormone-sensitive individuals |

Qualitative markers are often more informative than labs for this compound:

* Sleep quality and time to fall asleep
* Daytime calm versus residual grogginess
* Anxiety and stress levels
* Energy and general wellbeing

  
## Emerging Research

Research on apigenin is expanding from its preclinical base toward small human trials, with the central open questions being whether its animal-model benefits and NAD+-preserving mechanism translate to people, and whether better delivery can overcome its poor absorption. Both strengthening and weakening findings are possible from the work underway.

* **Apigenin in elderly sepsis (completed pilot):** [NCT05999682](https://clinicaltrials.gov/study/NCT05999682) — a completed Phase 1/2 study (20 participants) adding apigenin to standard care and tracking 96-hour organ-function (SOFA) scores, one of the few human trials of the isolated compound and a test of its anti-inflammatory promise.

* **Apigenin for post-viral inflammation (not yet recruiting):** [NCT07397910](https://clinicaltrials.gov/study/NCT07397910) — a planned trial (40 participants) evaluating an apigenin-based natural compound on the immune-inflammatory profile of Long COVID, probing whether apigenin dampens chronic inflammation in humans.

* **Liposomal apigenin in bone regeneration (enrolling by invitation):** [NCT07678749](https://clinicaltrials.gov/study/NCT07678749) — a trial (22 participants) using a liposomal apigenin-loaded scaffold during sinus-lift bone grafting, illustrating the shift toward enhanced-delivery formulations that could weaken or strengthen the bioavailability critique.

* **Apigenin absorption and metabolism (completed):** [NCT03526081](https://clinicaltrials.gov/study/NCT03526081) — a completed pharmacokinetic study (17 participants) measuring apigenin and its glycosides in blood and urine, directly addressing the bioavailability question that limits translation.

* **Future direction — human NAD+ testing:** The longevity case rests on the CD38/NAD+ mechanism established in animals by Escande et al., 2013 ([PMID 23172919](https://pubmed.ncbi.nlm.nih.gov/23172919/)); whether oral apigenin raises NAD+ or affects aging markers in humans is untested and is the single most important gap.

* **Future direction — sleep and aging translation:** The synthesis by Kramer & Johnson, 2024 ([PMID 38476603](https://pubmed.ncbi.nlm.nih.gov/38476603/)) maps the sleep–aging intersection and highlights the need for controlled human trials of isolated apigenin, along with improved-bioavailability formulations, to confirm or refute the preclinical signals.

  
## Conclusion

Apigenin is a plant flavonoid, most familiar as the calming ingredient in chamomile, that has drawn interest as a low-cost supplement for sleep, calm, and long-term cellular health. Its appeal to the longevity-minded rests largely on laboratory work showing it can slow the breakdown of a key cellular coenzyme that falls with age, alongside broad anti-inflammatory, antioxidant, and anticancer activity in cells and animals.

The gap between that promise and proven human benefit is wide. The most human-tested use — better sleep and reduced anxiety — comes mainly from chamomile studies and is modest and inconsistent, and the metabolic and anti-inflammatory signals, while biologically reasonable, rest on small or indirect trials. The headline longevity and cancer rationales remain based on cells and animals, and apigenin's poor absorption raises real doubt about how much reaches the body's tissues.

On safety, apigenin appears well tolerated at typical doses, with the main practical concern being its potential to interfere with the breakdown of medications and to add to the effects of blood thinners, sedatives, and hormone-related therapies. Overall, apigenin is an inexpensive, low-risk, and scientifically intriguing compound whose everyday calming benefits are gently supported while its more ambitious health and longevity claims stay unproven and genuinely uncertain.

  
**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**